Angiopoietins bind thrombomodulin and inhibit its function as a thrombin cofactor

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Daly, Christopher ^a   Qian, Xiaozhong ^a   Castanaro, Carla ^a   Pasnikowski, Elizabeth ^a   Jiang, Xiabo ^a   Thomson, Benjamin R ^b   Quaggin, Susan E ^b   Papadopoulos, Nicholas ^a   Wei, Yang ^a   Rudge, John S ^a   Thurston, Gavin ^a   Yancopoulos, George D ^a   Davis, Samuel ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; PROTEIN BINDING; PROTEIN C; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOMODULIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CV-1 CELL LINE; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE; RNA INTERFERENCE; THROMBOCYTE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; BLOOD PLATELETS; CARBOXYPEPTIDASE B2; CERCOPITHECUS AETHIOPS; COS CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; PLATELET FACTOR 4; PROTEIN BINDING; PROTEIN C; RECEPTOR, TIE-2; RECOMBINANT PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; THROMBIN; THROMBOMODULIN;

EID: 85040455418     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-18912-8     Document Type: Article

References (85)

1. Dumont, D. J. et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8, 1897-1909 (1994)
2. Dumont, D. J., Yamaguchi, T. P., Conlon, R. A., Rossant, J. & Breitman, M. L. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7, 1471-1480 (1992)
3. Sato, T. N. et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376, 70-74 (1995)
4. Davis, S. et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87, 1161-1169 (1996)
5. Maisonpierre, P. C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997)
6. Valenzuela, D. M. et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 96, 1904-1909 (1999)
7. Augustin, H. G., Koh, G. Y., Thurston, G. & Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10, 165-177 (2009)
8. Saharinen, P., Eklund, L. & Alitalo, K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov (2017)
9. Suri, C. et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 (1996)
10. Thurston, G. et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6, 460-463 (2000)
11. Thurston, G. et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514 (1999)
12. Daly, C. et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18, 1060-1071 (2004)
13. Kim, I. et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86, 24-29 (2000)
14. Papapetropoulos, A. et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275, 9102-9105 (2000)
15. Saharinen, P. et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10, 527-537 (2008)
16. Daly, C. et al. Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells. Proc Natl Acad Sci USA 103, 15491-15496 (2006)
17. Kim, I. et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 19, 4549-4552 (2000)
18. Teichert-Kuliszewska, K. et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 49, 659-670 (2001)
19. Kim, M. et al. Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin Invest 126, 3511-3525 (2016)
20. Korhonen, E. A. et al. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest 126, 3495-3510 (2016)
21. Leppanen, V. M., Saharinen, P. & Alitalo, K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci USA 114, 4376-4381 (2017)
22. Seegar, T. C. et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 37, 643-655 (2010)
23. Thurston, G. & Daly, C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med 2, a006550 (2012)
24. Yu, X. et al. Structural basis for angiopoietin-1-mediated signaling initiation. Proc Natl Acad Sci USA 110, 7205-7210 (2013)
25. Daly, C. et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73, 108-118 (2013)
26. Benest, A. V. et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One 8, e70459 (2013)
27. Bhandari, V. et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 12, 1286-1293 (2006)
28. David, S. et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Crit Care Med 40, 3034-3041 (2012)
29. Fiedler, U. et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12, 235-239 (2006)
30. Han, S. et al. Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med 8, 335ra355 (2016)
31. Parikh, S. M. et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 3, e46 (2006)
32. Scholz, A. et al. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 118, 5050-5059 (2011)
33. Tabruyn, S. P. et al. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am J Pathol 177, 3233-3243 (2010)
34. Ziegler, T. et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest (2013)
35. Gallagher, D. C. et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin Cancer Res 13, 2115-2120 (2007)
36. Giuliano, J. S. Jr. et al. Admission angiopoietin levels in children with septic shock. Shock 28, 650-654 (2007)
37. Orfanos, S. E. et al. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 35, 199-206 (2007)
38. Siner, J. M., Bhandari, V., Engle, K. M., Elias, J. A. & Siegel, M. D. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 31, 348-353 (2009)
39. Bezuidenhout, L., Zilla, P. & Davies, N. Association of Ang-2 with integrin beta 2 controls Ang-2/PDGF-BB-dependent upregulation of human peripheral blood monocyte fibrinolysis. Inflammation 32, 393-401 (2009)
40. Carlson, T. R., Feng, Y., Maisonpierre, P. C., Mrksich, M. & Morla, A. O. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 276, 26516-26525 (2001)
41. Cascone, I., Napione, L., Maniero, F., Serini, G. & Bussolino, F. Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol 170, 993-1004 (2005)
42. Dallabrida, S. M., Ismail, N., Oberle, J. R., Himes, B. E. & Rupnick, M. A. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96, e8-24 (2005)
43. Felcht, M. et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 122, 1991-2005 (2012)
44. Imanishi, Y. et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res 67, 4254-4263 (2007)
45. Hakanpaa, L. et al. Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat Commun 6, 5962 (2015)
46. Lee, J. et al. Angiopoietin-1 guides directional angiogenesis through integrin alphavbeta5 signaling for recovery of ischemic retinopathy. Sci Transl Med 5, 203ra127 (2013)
47. Esmon, C. T., Esmon, N. L. & Harris, K. W. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257, 7944-7947 (1982)
48. Owen, W. G. & Esmon, C. T. Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256, 5532-5535 (1981)
49. Van de Wouwer, M., Collen, D. & Conway, E. M. Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 24, 1374-1383 (2004)
50. Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101, 1983-1991 (1998)
51. Esmon, C. T. & Owen, W. G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78, 2249-2252 (1981)
52. Davis, S. et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10, 38-44 (2003)
53. Barton, W. A., Tzvetkova, D. & Nikolov, D. B. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure 13, 825-832 (2005)
54. Barton, W. A. et al. Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nature structural & molecular biology 13, 524-532 (2006)
55. Hackeng, T. M. et al. Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin. Biochem J 319(Pt 2), 399-405 (1996)
56. Hockin, M. F., Kalafatis, M., Shatos, M. & Mann, K. G. Protein C activation and factor Va inactivation on human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 17, 2765-2775 (1997)
57. Slungaard, A. et al. Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102, 146-151 (2003)
58. Fukudome, K. & Esmon, C. T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269, 26486-26491 (1994)
59. Stearns-Kurosawa, D. J., Kurosawa, S., Mollica, J. S., Ferrell, G. L. & Esmon, C. T. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 93, 10212-10216 (1996)
60. Laszik, Z. et al. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 96, 3633-3640 (1997)
61. Tsiang, M., Lentz, S. R. & Sadler, J. E. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 267, 6164-6170 (1992)
62. Kokame, K., Zheng, X. & Sadler, J. E. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 273, 12135-12139 (1998)
63. Li, J. J., Huang, Y. Q., Basch, R. & Karpatkin, S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85, 204-206 (2001)
64. Nadar, S. K., Blann, A. D. & Lip, G. Y. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. J Intern Med 256, 331-337 (2004)
65. Peterson, J. E. et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 85, 487-493 (2010)
66. Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103, 4150-4156 (2004)
67. Goede, V. et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 103, 1407-1414 (2010)
68. Wang, X. et al. The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol 7, 188-195 (2014)
69. Kowalska, M. A., Mahmud, S. A., Lambert, M. P., Poncz, M. & Slungaard, A. Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood 110, 1903-1905 (2007)
70. Jeansson, M. et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest 121, 2278-2289 (2011)
71. Logothetidou, A. et al. Stereological and immunogold studies on TIE1 and TIE2 localization in glomeruli indicate angiopoietin signaling in podocytes. Micron 97, 6-10 (2017)
72. Gale, N. W. et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3, 411-423 (2002)
73. Oliner, J. et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516 (2004)
74. Karlan, B. Y. et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30, 362-371 (2012)
75. Monk, B. J. et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15, 799-808 (2014)
76. Herbst, R. S. et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27, 3557-3565 (2009)
77. Joyce, D. E., Gelbert, L., Ciaccia, A., DeHoff, B. & Grinnell, B. W. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276, 11199-11203 (2001)
78. Danese, S., Vetrano, S., Zhang, L., Poplis, V. A. & Castellino, F. J. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 115, 1121-1130 (2010)
79. Lay, A. J., Donahue, D., Tsai, M. J. & Castellino, F. J. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 109, 1984-1991 (2007)
80. Griffin, J. H., Zlokovic, B. V. & Mosnier, L. O. Activated protein C: biased for translation. Blood 125, 2898-2907 (2015)
81. Campbell, W. D., Lazoura, E., Okada, N. & Okada, H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiology and immunology 46, 131-134 (2002)
82. Myles, T. et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278, 51059-51067 (2003)
83. Minhas, N., Xue, M. & Jackson, C. J. Activated protein C binds directly to Tie2: possible beneficial effects on endothelial barrier function. Cell Mol Life Sci 74, 1895-1906 (2017)
84. Davis, S. et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266, 816-819 (1994)
85. Peters, K. G. et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer 77, 51-56 (1998).